Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 2, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how treating severe gum disease (periodontitis) might affect inflammation in the arteries of patients who have recently had a heart attack (acute myocardial infarction). The trial involves two groups: one group will receive special dental care from periodontists, while the other group will receive standard dental treatment from regular dental surgeons. Both groups will have their levels of inflammation in the arteries checked using a special imaging test at the beginning of the trial and again after one year.

To be eligible for this trial, participants must have had a heart attack and show signs of severe gum disease, meaning they need to have at least six teeth (not counting wisdom teeth) and score a certain level on a screening tool. Participants should also be able to attend follow-up visits and agree to take part in the study by signing consent. Throughout the study, those in the intervention group will receive dental care for up to six months, followed by another six months of check-ins to see how they are doing. This trial is important because it may help us understand the relationship between gum health and heart health, which could lead to better treatments for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients hospitalized for an acute myocardial infarction and included in the Frenchie registry
• • Score ≥ 5 on the screening questionnaire for periodontitis
• • Six teeth at least (excluding wisdom teeth)
• • Consent signature
• • Affiliation to a French medical insurance (Sécurité Sociale)
• Exclusion Criteria:
• • Patients with diseases,other than cardiovascular and diabetes, known to change the periodontal state such as AIDS, rheumatoid arthritis, Chediak-Higashi syndrome, Papillon-Lefèvre
• • Systemic antibiotic therapy\> 48 hours in the 3 months prior to inclusion
• • Acute heart failure
• • Uncontrolled ventricular rhythm disorders
• • Impossibility for the patient to attend follow-up visits
• • Impossibility to maintain the extended position for 20 minutes
• • Immunosuppressive therapy\> 1 month in the 6 months prior to inclusion
• • Pregnancy, breastfeeding
• • Known hypersensitivity to chlorhexidine, povidone, 18-fluoro-deoxyglucose

Trial Officials